Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Johnson

Showing results (331-340 of 349) with videos related to

Pageof 35
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
European Journal of Human Genetics : EJHG|November 19, 2015
Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionalsMelissa Hill, Jo-Ann Johnson, Sylvie Langlois, et al.
Nature Medicine|October 10, 2023
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|September 18, 2016
Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer TestingR Douglas Wilson, Isabelle De Bie, Christine M Armour, et al.
Journal of the American College of Cardiology|December 24, 2011
Hypoplastic left heart syndrome: current considerations and expectationsJeffrey A Feinstein, D Woodrow Benson, Anne M Dubin, et al.
Cell Host & Microbe|December 18, 2021
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variantsChang Liu, Daming Zhou, Rungtiwa Nutalai, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Cell|June 30, 2022
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serumAekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
World Journal of Surgery|May 4, 2026
Open Versus Hybrid and Total Minimally Invasive Transthoracic Ivor Lewis Esophagectomy Following Neoadjuvant FLOT Chemotherapy: An Australian and New Zealand Cohort StudyBrendan Desmond, Maneesha De Silva, Darren J Wong, et al.
Pageof 35

Showing results (331-340 of 349) with videos related to

Sort By:
Pageof 35
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
European Journal of Human Genetics : EJHG|November 19, 2015
Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionalsMelissa Hill, Jo-Ann Johnson, Sylvie Langlois, et al.
Nature Medicine|October 10, 2023
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|September 18, 2016
Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer TestingR Douglas Wilson, Isabelle De Bie, Christine M Armour, et al.
Journal of the American College of Cardiology|December 24, 2011
Hypoplastic left heart syndrome: current considerations and expectationsJeffrey A Feinstein, D Woodrow Benson, Anne M Dubin, et al.
Cell Host & Microbe|December 18, 2021
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variantsChang Liu, Daming Zhou, Rungtiwa Nutalai, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Cell|June 30, 2022
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serumAekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
World Journal of Surgery|May 4, 2026
Open Versus Hybrid and Total Minimally Invasive Transthoracic Ivor Lewis Esophagectomy Following Neoadjuvant FLOT Chemotherapy: An Australian and New Zealand Cohort StudyBrendan Desmond, Maneesha De Silva, Darren J Wong, et al.
Pageof 35